Keck School Faculty

Nada Elbuluk
Nada Elbuluk
Clinical Assistant Professor of Dermatology (Clinician Educator)
Dermatology
1450 San Pablo St. Health Sciences Campus Los Angeles
Dr. Nada Elbuluk is a board-certified dermatologist and Assistant Professor at the USC Keck School of Medicine, Department of Dermatology. She is honored to be a dermatologist at USC and to be able to serve the diverse population of Los Angeles. She is the founder and director of the USC Skin of Color Center and Pigmentary Disorders Clinic. She also serves as the Director of the Dermatology Diversity and Inclusion Program.

Dr. Elbuluk’s clinical and research interests include general medical and cosmetic dermatology,
ethnic skin conditions, and pigmentary disorders including vitiligo, melasma, and postinflammatory pigmentation. She performs a variety of procedures including chemical peels, microneedling, lasers, and botox and has expertise in safely performing these procedures in all skin types.

Dr. Elbuluk received her bachelor’s degree in Psychology from Princeton University where she also minored in Gender Studies and African American Studies. She completed her medical degree at the University of Michigan where she graduated with a Distinction in Research. While there, she received a National Institute of Health award that allowed her to also obtain a Master of Science in Clinical Research from the University of Michigan School of Public Health. She completed her dermatology residency at Johns Hopkins Hospital. Afterwards, she was a fellow and clinical instructor in the Dermatology Department at The University of Pennsylvania. She then spent four years as an Assistant Professor at New York University’s School of Medicine, where she was the founder and director of the pigmentary disorder clinic and served as the Diversity Ambassador for the Department.

Dr. Elbuluk feels strongly about providing her patients with the highest quality of individualized and compassionate care. She also is passionate about teaching and advancing the field of dermatology through research on pigmentary disorders and ethnic skin conditions. She has received several grants to support her research, which has been published in numerous academic journals. She has lectured both national and internationally on her areas of expertise. She also serves as a media expert for the American Academy of Dermatology and has been interviewed by numerous media outlets including the Washington Post, Health, Women’s Health, Essence, Prevention, Allure, Reader’s Digest, the Huffington Post, SELF, and NBC.com.

Dr. Elbuluk is a Diplomate of the American Academy of Dermatology and holds professional memberships with the American Academy of Dermatology, the Women’s Dermatologic Society, the American Society for Dermatologic Surgery, and the Skin of Color Society.

International Initiative for outcomes (INFO) for vitiligo: Workshops with vitiligo patients on repigmentation Br J Dermatol. 2018 Jul 21. . View in PubMed

Beyond Traditional Treatment: The Importance of Psychosocial Therapy in Vitiligo J Drugs Dermatol. 2018 Jun 01; 17(6):688-691. . View in PubMed

Disparity in Cutaneous Pigmentary Response to LED vs Halogen Incandescent Visible Light: Results from a Single Center, Investigational Clinical Trial Determining a Minimal Pigmentary Visible Light Dose J Drugs Dermatol. 2017 Nov 01; 16(11):1105-1110. . View in PubMed

Melasma: an Up-to-Date Comprehensive Review Dermatol Ther (Heidelb). 2017 Sep; 7(3):305-318. . View in PubMed

The nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant response promotes melanocyte viability and reduces toxicity of the vitiligo-inducing phenol monobenzone Exp Dermatol. 2017 Jul; 26(7):637-644. . View in PubMed

Quality of Life, Burden of Disease, Co-morbidities, and Systemic Effects in Vitiligo Patients Dermatol Clin. 2017 Apr; 35(2):117-128. . View in PubMed

A Difference in Cutaneous Pigmentary Response to LED Versus Halogen Incandescent Visible Light: A Case Report from a Single Center, Investigational Clinical Trial Determining a Minimal Pigmentary Visible Light Dose J Drugs Dermatol. 2017 Apr 01; 16(4):388-392. . View in PubMed

Microneedling: A Comprehensive Review Dermatol Surg. 2017 Mar; 43(3):321-339. . View in PubMed

Daily indoor light exposure: A spectral analysis of ambient light sources and its relevance to occupational dermatology J Am Acad Dermatol. 2017 04; 76(4):763-765. . View in PubMed

Advances in Vitiligo: An Update on Medical and Surgical Treatments J Clin Aesthet Dermatol. 2017 Jan; 10(1):15-28. . View in PubMed

Lichen planus pigmentosus and lichen planopilaris Dermatol Online J. 2016 Dec 15; 22(12). . View in PubMed

Lichen planus pigmentosus Dermatol Online J. 2016 Dec 15; 22(12). . View in PubMed

Common conditions in skin of color Semin Cutan Med Surg. 2016 Dec; 35(4):184-190. . View in PubMed

Infrared irradiation differentially alters collagen metabolism in lightly and darkly pigmented human skin in vivo J Dermatol Sci. 2016 Jun; 82(3):212-4. . View in PubMed

Microneedling in skin of color: A review of uses and efficacy J Am Acad Dermatol. 2016 Feb; 74(2):348-55. . View in PubMed

Cutaneous Rosai-Dorfman Disease in a Patient with Human Immunodeficiency Virus Dermatol Online J. 2016 Jan 15; 22(1). . View in PubMed

Recent advances in understanding vitiligo F1000Res. 2016; 5. . View in PubMed

Alternative Systemic Treatments for Vitiligo: A Review Am J Clin Dermatol. 2015 Dec; 16(6):463-74. . View in PubMed

Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses Am J Pathol. 2011 Apr; 178(4):1434-41. . View in PubMed

Cutis. 2011 Feb; 87(2):65, 76-7. . View in PubMed

Erythema nodosum leprosum, Sweet's syndrome, and human immunodeficiency virus may be related through an overlap in immunopathogenesis Int J Dermatol. 2010 Nov; 49(11):1344-5. . View in PubMed

Retinoic acid 4-hydroxylase inducibility and clinical response to isotretinoin in patients with acne J Am Acad Dermatol. 2009 Aug; 61(2):252-8. . View in PubMed

Powered by SC CTSI
Go to Top